PMID- 38332683
OWN - NLM
STAT- MEDLINE
DCOM- 20240220
LR  - 20240220
IS  - 1523-5378 (Electronic)
IS  - 1083-4389 (Linking)
VI  - 29
IP  - 1
DP  - 2024 Jan-Feb
TI  - Eradication rate and adherence with high-dose amoxicillin and proton pump 
      inhibitor as first-line treatment for Helicobacter pylori infection: Experience 
      from University Hospital in Chile.
PG  - e13052
LID - 10.1111/hel.13052 [doi]
AB  - INTRODUCTION: In Chile, more than 70% of adults are infected by Helicobacter 
      pylori. Clarithromycin should not be used in any regimen if there is >15% 
      resistance to this antibiotic, being greater than 26% in our population. In this 
      scenario, the effectiveness of triple therapy (proton pump inhibitor [PPI], 
      clarithromycin, amoxicillin) was only 63.8%. AIM: To evaluate the eradication 
      rate and safety of dual therapy (esomeprazole and amoxicillin) in high doses, 
      through a prospective, observational, and descriptive study. METHODS: Patients 
      with a positive urease test obtained in an upper digestive endoscopy were 
      included. Any other previous H. pylori eradication regimen were excluded. All 
      patients were treated with esomeprazole 40 mg three times a day and amoxicillin 
      750 mg four times a day for 14 days. The eradication rate of the dual therapy was 
      evaluated with the H. pylori stool antigen test (the Pylori-Strip(R) test used) 
      6 weeks after completing the eradication treatment and with at least 14 days 
      without PPI, being a negative result, confirmation of the effectiveness of this 
      regimen. RESULTS: Of 122 patients, 106 had a negative H. pylori antigen in stool; 
      The intention-to-treat and per protocol analysis, the eradication rates were 
      91.8% [95% CI: 87%-97%] and 94% [95% CI: 90%-98%], respectively. Four patients 
      discontinued treatment due to adverse effects. Smoking and adherence to treatment 
      were associated with eradication rate. CONCLUSIONS: In this cohort of patients 
      with H. pylori infection, high-dose dual therapy has a high eradication rate and 
      good adherence, raising the possibility that it could be used as first-line 
      therapy in our country. Studies with a larger number of patients should confirm 
      these results.
CI  - (c) 2024 John Wiley & Sons Ltd.
FAU - von Muhlenbrock, Christian
AU  - von Muhlenbrock C
AUID- ORCID: 0000-0001-5285-1147
AD  - Digestive Diseases Center, Clinica Universidad de los Andes, Universidad de los 
      Andes, Santiago, Chile.
AD  - Gastroenterology Section, Hospital Clinico Universidad de Chile, Santiago, Chile.
FAU - Cordova, Andrea
AU  - Cordova A
AD  - Digestive Diseases Center, Clinica Universidad de los Andes, Universidad de los 
      Andes, Santiago, Chile.
FAU - Nunez, Paulina
AU  - Nunez P
AUID- ORCID: 0000-0003-3727-1851
AD  - Digestive Diseases Center, Clinica Universidad de los Andes, Universidad de los 
      Andes, Santiago, Chile.
AD  - Gastroenterology Section, Hospital San Juan de Dios, Facultad Medicina 
      Universidad de Chile Sede Occidente, Santiago, Chile.
FAU - Pacheco, Nicole
AU  - Pacheco N
AD  - Digestive Diseases Center, Clinica Universidad de los Andes, Universidad de los 
      Andes, Santiago, Chile.
FAU - Herrera, Karin
AU  - Herrera K
AUID- ORCID: 0000-0003-1841-5266
AD  - Digestive Diseases Center, Clinica Universidad de los Andes, Universidad de los 
      Andes, Santiago, Chile.
AD  - Nutrition and Food Sciences Ph.D. Program, University of Granada, Granada, Spain.
FAU - Quera, Rodrigo
AU  - Quera R
AUID- ORCID: 0000-0001-5854-0526
AD  - Digestive Diseases Center, Clinica Universidad de los Andes, Universidad de los 
      Andes, Santiago, Chile.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - England
TA  - Helicobacter
JT  - Helicobacter
JID - 9605411
RN  - 804826J2HU (Amoxicillin)
RN  - 0 (Anti-Bacterial Agents)
RN  - H1250JIK0A (Clarithromycin)
RN  - N3PA6559FT (Esomeprazole)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Amoxicillin
MH  - Anti-Bacterial Agents
MH  - Chile
MH  - Clarithromycin/therapeutic use
MH  - Drug Therapy, Combination/adverse effects
MH  - Esomeprazole/therapeutic use
MH  - *Helicobacter Infections/drug therapy
MH  - *Helicobacter pylori
MH  - Hospitals
MH  - Prospective Studies
MH  - Proton Pump Inhibitors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Helicobacter pylori
OT  - Chile
OT  - amoxicillin dual therapy
OT  - antibiotics
EDAT- 2024/02/09 06:42
MHDA- 2024/02/10 14:47
CRDT- 2024/02/09 02:43
PHST- 2024/01/09 00:00 [revised]
PHST- 2023/09/15 00:00 [received]
PHST- 2024/01/22 00:00 [accepted]
PHST- 2024/02/10 14:47 [medline]
PHST- 2024/02/09 06:42 [pubmed]
PHST- 2024/02/09 02:43 [entrez]
AID - 10.1111/hel.13052 [doi]
PST - ppublish
SO  - Helicobacter. 2024 Jan-Feb;29(1):e13052. doi: 10.1111/hel.13052.